XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended 9 Months Ended
Sep. 30, 2024
shares
Sep. 30, 2024
shares
Trading Arrangements, by Individual    
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Daniel Skovronsky [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
On September 11, 2024, Daniel Skovronsky, M.D., Ph.D., executive vice president, chief scientific officer and president, Lilly research laboratories and Lilly immunology, adopted a sales plan (Plan). The Plan was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act of 1934 and our policies regarding trading in our securities. The Plan calls for the sale of up to 5,000 shares of company common stock between February 10, 2025 and September 8, 2025 subject to the terms and conditions of the Plan.
Name Daniel Skovronsky  
Title executive vice president, chief scientific officer and president  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date September 11, 2024  
Expiration Date September 8, 2025  
Arrangement Duration 210 days  
Aggregate Available 5,000 5,000